API Manufacturers in India Trusted by Global Pharma Companies

Why Shilpa Pharma is Among the Most Trusted API Manufacturers in India

India has emerged as the world’s preferred destination for high-quality API manufacturing — and Shilpa Pharma has been at the forefront of this growth for decades. As a full-scale API manufacturing company in India, Shilpa combines deep therapeutic expertise, advanced infrastructure, and global regulatory compliance to serve pharmaceutical companies across more than 80 countries. From oncology and high-potency APIs to peptides and cardiovascular molecules, Shilpa offers a comprehensive and reliable API supply chain built for the demands of global pharma.

As one of the leading API manufacturers in India, Shilpa Pharma serves both regulated markets (US, EU, Japan, Australia) and semi-regulated markets with equal consistency. Whether you need a single-source supplier for a complex oncology molecule or a CDMO partner for end-to-end API development, Shilpa’s integrated capabilities make it the preferred choice for top pharmaceutical brands worldwide.

Oncology API Manufacturers in India – Shilpa’s Flagship Strength

Among all therapeutic areas, oncology remains Shilpa Pharma’s most recognized and established expertise. As one of India’s leading oncology API manufacturers, Shilpa maintains a broad portfolio of high-potency molecules that are critical to modern cancer treatment. The company’s oncology API capabilities span a wide range of drug classes including alkylating agents, antimetabolites, kinase inhibitors, and hormone-based therapies.

Shilpa’s oncology APIs are manufactured at cGMP-compliant facilities approved by USFDA, EU GMP, ANVISA, COFEPRIS, TGA, PMDA, and KFDA. This ensures that every API produced meets the most stringent quality and regulatory requirements, allowing global pharmaceutical companies to confidently source molecules for both branded and generic oncology drug development.

High Potent API (HPAPI) Manufacturing at Shilpa

HPAPIs (High Potent Active Pharmaceutical Ingredients) are compounds that are effective at extremely low doses and are commonly used in cancer and hormone therapies. Manufacturing these substances requires specialized containment systems, advanced process controls, and highly trained personnel to ensure both product integrity and operator safety.

Shilpa is among the few HPAPI manufacturers in India with the dedicated infrastructure and multi-regulatory approvals to produce high potent APIs safely and at commercial scale. The company’s HPAPI manufacturing capabilities include handling of cytotoxic and cytostatic compounds — molecules that are essential for advanced oncology treatments such as antibody-drug conjugates (ADCs) and targeted cancer therapies. With occupational exposure band (OEB) classification systems, isolator technology, and closed-system processing, Shilpa ensures full containment compliance throughout the manufacturing lifecycle.

What is an Oncology API?

An Oncology API is an Active Pharmaceutical Ingredient specifically developed for use in cancer treatment drugs. APIs are the biologically active components in any pharmaceutical formulation — they produce the intended therapeutic effect in the patient. In oncology, these APIs are designed to target cancer cells, inhibit tumor growth, or sensitize malignant cells to radiation and other therapies.

Given their high potency and complex synthesis requirements, oncology APIs demand a higher level of manufacturing expertise, containment infrastructure, and analytical rigor compared to conventional APIs. This is why sourcing from an experienced and globally certified oncology API manufacturer in India like Shilpa Pharma is critical for pharmaceutical companies developing cancer therapies.

Peptide API Manufacturing in India

In addition to its oncology leadership, Shilpa is an established peptide API manufacturer in India, supporting the growing global demand for peptide-based therapeutics. Peptide APIs are used across a wide range of conditions including metabolic disorders, oncology, cardiovascular diseases, and hormonal therapies. Shilpa’s peptide manufacturing capabilities include both solid-phase and liquid-phase synthesis, supported by advanced purification and analytical characterization technologies.

As the market for GLP-1 agonists, ADC payloads, and other peptide-based drugs continues to expand, Shilpa’s peptide API capabilities position it as a forward-looking pharmaceutical API manufacturer in India ready to support next-generation drug development.

API Intermediates Manufacturing

Shilpa is also a trusted API intermediate manufacturer in India, producing key chemical intermediates that are used in the synthesis of finished APIs. These intermediates are supplied to pharmaceutical companies globally, supporting both in-house API production and outsourced manufacturing programs. Shilpa’s intermediate manufacturing capabilities are backed by robust process chemistry expertise, ensuring consistent purity, yield, and scalability at every stage of synthesis.

Whether you need intermediates for oncology molecules, cardiovascular APIs, or CNS compounds, Shilpa provides reliable supply with full documentation support for regulatory submissions.

Broad API Capabilities Across Therapeutic Areas

While oncology and HPAPIs define Shilpa’s flagship identity, the company’s API manufacturing capabilities extend across multiple therapeutic categories. As a diversified API drug manufacturer in India, Shilpa’s portfolio includes APIs for:

• Oncology – High-potency cytotoxic and targeted therapy APIs
• Cardiovascular – Statins, antihypertensives, anticoagulants
• CNS – Antidepressants, antiepileptics, neuroprotective agents
• Antiviral – APIs for HIV, Hepatitis, and emerging viral conditions
• Peptides – Metabolic, hormonal, and oncology peptide APIs
• API Intermediates – Key synthesis intermediates across all therapeutic areas

This therapeutic breadth makes Shilpa a single, reliable pharmaceutical API supplier in India for companies managing multi-product drug pipelines across global markets.

Global Regulatory Approvals and Compliance

As a globally recognized API supplier in India, Shilpa’s manufacturing facilities are certified by the world’s most respected pharmaceutical regulatory authorities. These approvals validate Shilpa’s commitment to quality, safety, and compliance at every stage of API production.

Our facilities hold approvals from:

• USFDA Approved – United States Food & Drug Administration
• EU GMP Certified – European Union Good Manufacturing Practice
• ANVISA Approved – Brazilian Health Regulatory Agency
• COFEPRIS Approved – Federal Commission for Protection against Sanitary Risks, Mexico
• TGA Certified – Therapeutic Goods Administration, Australia
• PMDA Approved – Pharmaceuticals and Medical Devices Agency, Japan
• KFDA Certified – Korea Food & Drug Administration, South Korea

These certifications position Shilpa Pharma as a trusted API manufacturing company in India for both regulated and semi-regulated markets, ensuring pharmaceutical partners can confidently use Shilpa-sourced APIs in their global regulatory submissions.

Why Choose Shilpa as Your API Manufacturing Partner in India?

• Decades of API manufacturing expertise across oncology, peptides, cardiovascular, CNS, and antiviral therapeutic areas
• One of India’s few dedicated HPAPI manufacturers with cytotoxic containment infrastructure and OEB-classified processes
• 7 major global regulatory approvals including USFDA, EU GMP, TGA, PMDA, and KFDA
• End-to-end CDMO capabilities from early R&D and process development to commercial-scale API production
• Trusted pharmaceutical API supplier to leading global pharma brands across 80+ countries
• Comprehensive regulatory documentation support including DMFs, CEPs, and IPR assistance for global submissions
• Diversified API and intermediate portfolio enabling single-source supply for complex multi-product pipelines